AI
Saudi Arabia
UAE
EgyptQatar’s AI Startup Lillia Secures $1.7M to Transform Chronic Disease Care
2 min
Lillia received a $1,7M grant from the QRDI Council to push forward AI-driven chronic disease solutions.
The company is building digital twin technology, a real-time AI model that helps monitor and predict health risks.
Lillia showcased its AI innovations at Web Summit Qatar, highlighting real-time risk monitoring and precision medication.
Formed through the 2024 merger of Droobi Health LLC (Qatar) and Smit,fit (India), Lillia is expanding into MENA and Southeast Asia.
Backed by Qatar Development Bank, QSTP, and M Venture Partners, the startup is shaping the future of AI-driven healthcare.
In a significant move for the region’s healthtech sector, Lillia, a Qatari AI-driven healthcare startup, has secured $1.7 million in funding from the Qatar Research, Development, and Innovation (QRDI) Council. The grant is dedicated to developing a groundbreaking digital twin system—an AI-powered tool designed to monitor, predict, and personalize care for chronic disease patients.
Bringing AI to Chronic Disease Management
Lillia’s digital twin technology is set to change the game for millions of people living with chronic conditions. The system continuously updates a virtual representation of a patient, integrating real-time health data with predictive analytics. By doing so, it can anticipate risks, recommend treatment adjustments, and support doctors, insurers, and healthcare providers in delivering more effective care.
Speaking on the impact of this innovation, Nada Al-Olaqi, Director of Innovation Development and Piloting Programs at QRDI Council, emphasized:
"Through our Technology Development Grant program, we empower pioneering companies like Lillia to bring transformative technology solutions to life, advancing healthcare, enhancing quality of life, and positioning Qatar as a leader in digital transformation."
Lillia’s AI platform was officially unveiled at Web Summit Qatar, where the team demonstrated how digital twins—when combined with AI agents—can provide real-time risk monitoring, predictive healthcare solutions, and precision medication recommendations.
The Journey Behind Lillia
The startup is a product of a 2024 merger between Qatar-based Droobi Health LLC and India’s Smit.fit, two pioneers in AI-powered chronic disease management. Under the leadership of founder and CEO Sujit Chakrabarty, Lillia’s mission is clear:
"Lillia exists to lower the chronic disease burden for the world by providing continuous adaptive care that drives a real and lasting lifestyle change."
Global Expansion and Investor Backing
With the grant in hand, Lillia is setting its sights on expanding across MENA and Southeast Asia, positioning itself as a key player in AI-powered healthcare. The startup has also garnered strong investor support, with funding from Qatar Development Bank, QSTP, and M Venture Partners, all betting on its potential to reshape the future of chronic disease care.
As the healthcare industry moves toward more AI-driven, patient-centric solutions, Lillia’s innovative technology may become a cornerstone in the fight against chronic diseases—not just in Qatar, but on a global scale.
